Peng L - Search Results

1

Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.

Ye X, Yang J, Stebbing J, Peng L. Ye X, et al. Among authors: peng l. BMC Pulm Med. 2022 Feb 5;22(1):54. doi: 10.1186/s12890-022-01846-x. BMC Pulm Med. 2022. PMID: 35123465 Free PMC article.

2

Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Ye XH, Bu ZB, Feng J, Peng L, Liao XB, Zhu XL, Sun XL, Yu HG, Yan DF, Yan SX. Ye XH, et al. Among authors: peng l. Mol Biol Rep. 2014 Jan;41(1):373-85. doi: 10.1007/s11033-013-2871-1. Epub 2013 Nov 23. Mol Biol Rep. 2014. PMID: 24271138

3

Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis.

Peng L, Bu Z, Zhou Y, Ye X, Liu J, Zhao Q. Peng L, et al. Tumour Biol. 2014 Sep;35(9):9419-27. doi: 10.1007/s13277-014-2189-1. Epub 2014 Jun 24. Tumour Biol. 2014. PMID: 24957040

4

Peng L, Zhou Y, Ye X, Zhao Q. Peng L, et al. Tumour Biol. 2015 Feb;36(2):643-54. doi: 10.1007/s13277-014-2669-3. Epub 2014 Oct 4. Tumour Biol. 2015. PMID: 25281033

5

Association between the CYP2E1 polymorphisms and lung cancer risk: a meta-analysis.

Ye XH, Song L, Peng L, Bu Z, Yan SX, Feng J, Zhu XL, Liao XB, Yu XL, Yan D. Ye XH, et al. Among authors: peng l. Mol Genet Genomics. 2015 Apr;290(2):545-58. doi: 10.1007/s00438-014-0941-2. Epub 2014 Oct 22. Mol Genet Genomics. 2015. PMID: 25336053

6

Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.

Peng L, Zhao Q, Ye X, Zhou Y, Hu D, Zheng S. Peng L, et al. PLoS One. 2014 Nov 3;9(11):e111839. doi: 10.1371/journal.pone.0111839. eCollection 2014. PLoS One. 2014. PMID: 25365378 Free PMC article. Review.

7

Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.

Peng L, Ye X, Zhou Y, Zhang J, Zhao Q. Peng L, et al. Support Care Cancer. 2015 Sep;23(9):2813-24. doi: 10.1007/s00520-015-2648-2. Epub 2015 Feb 13. Support Care Cancer. 2015. PMID: 25676487

8

Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients.

Peng L, Wang Y, Tang Y, Zeng L, Liu J, Zeng Z, Liu J, Shi P, Ye X, Zhao Q. Peng L, et al. Onco Targets Ther. 2017 Aug 28;10:4261-4267. doi: 10.2147/OTT.S143569. eCollection 2017. Onco Targets Ther. 2017. PMID: 28894381 Free PMC article.

9

Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis.

Peng L, Wang Y, Hong Y, Ye X, Shi P, Zhang J, Zhao Q. Peng L, et al. Oncotarget. 2017 Sep 19;8(47):83280-83291. doi: 10.18632/oncotarget.21059. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137342 Free PMC article.

10

Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis.

Peng L, Hong Y, Ye X, Shi P, Zhang J, Wang Y, Zhao Q. Peng L, et al. Oncotarget. 2017 Sep 19;8(67):112076-112084. doi: 10.18632/oncotarget.21057. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340112 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,194 results

Search Page

Filters